OGCT-03 PHASE I/IB STUDY OF CONCURRENT INTRAVENOUS (IV) AND INTRATHECAL (IT) NIVOLUMAB (N) AND RELATLIMAB (R) FOR METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH LEPTOMENINGEAL DISEASE (LMD)

Neurooncol Adv · 2025 · PMC12342474

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Preclinical models confirmed that the combined treatment with IT/IV anti-PD1/anti-LAG3 achieved highly significant improvement in OS.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.